Subscribe to RSS
Download PDF
DOI: 10.1160/TH12-05-0332
Unfavourable cardiovascular disease risk profiles in a cohort of Dutch and British haemophilia patients
Financial support: This study was supported by an unrestricted grant from CSL Behring to DEFvdP.
Publication History
Received:
20 May 2012
Accepted after minor revision:
17 September 2012
Publication Date:
27 November 2017 (online)
Summary
Cardiovascular disease (CVD) mortality is reported to be decreased in haemophilia patients, but reports on the prevalence of CVD risk factors are conflicting. A cross-sectional assessment of CVD risk profiles was performed in a large cohort of haemophilia patients. Baseline data on CVD risk factors of 709 Dutch and UK haemophilia patients aged ≥ 30 years were analysed and compared with the general age-matched male population. CVD risk profiles were assessed using the QRISK®2–2011 and SCORE algorithms. Although QRISK®2 was only validated in the UK, comparison with SCORE indicated similar properties of QRISK®2 in both Dutch and UK patients (correlation 0.86). Mean age was 49.8 years. Hypertension was more common in haemophilia patients than in the general population (49% vs. 40%), while the prevalences of obesity and hypercholesterolaemia were lower (15 vs. 20% and 44 vs. 68%, respectively), and those of diabetes and smoking were similar. The predicted 10-year QRISK®2 risk was significantly higher in haemophilia patients than in the general population (8.9 vs. 6.7%), indicating more unfavourable cardiovascular disease risk profiles. This increased risk became apparent after the age of 40 years. Our results indicate an increased prevalence of hypertension and overall more unfavourable CVD risk profiles in haemophilia patients compared with the general age-matched male population.
-
References
- 1 Plug I. et al. Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study. J Thromb Haemost 2006; 04: 510-516. DOI:10.1111/j.1538-7836.2006.01808.x.
- 2 Darby SC. et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007; 110: 815-825. DOI:10.1182/blood-2006-10-050435.
- 3 Koumbarelis E. et al. Epidemiology of haemophilia in Greece: an overview. Thromb Haemost 1994; 72: 808-813.
- 4 Rosendaal FR. et al. Haemophilia protects against ischaemic heart disease: a study of risk factors. Br J Haematol 1990; 75: 525-530. DOI:10.1111/j.1365-2141.1990.tb07793.x.
- 5 Siboni SM. et al. Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy. J Thromb Haemost 2009; 07: 780-786. DOI:10.1111/j.1538-7836.2009.03318.x.
- 6 Biere-Rafi S. et al. Cardiovascular risk assessment in haemophilia patients. Thromb Haemost 2011; 105: 274-278. DOI:10.1160/TH10-07-0460.
- 7 Lim MY, Pruthi RK. Cardiovascular disease risk factors: prevalence and management in adult hemophilia patients. Blood Coagul Fibrinolysis 2011; 22: 402-406. DOI:10.1097/MBC.0b013e328345f582.
- 8 Bilora F. et al. Does hemophilia protect against atherosclerosis? A case-control study. Clin Appl Thromb Hemost 2006; 12: 193-198. DOI:10.1177/107602960601200207.
- 9 Foley CJ. et al. Coronary atherosclerosis and cardiovascular mortality in hemophilia. J Thromb Haemost 2010; 08: 208-211. DOI:10.1111/j.1538-7836.2009.03669.x.
- 10 Walsh M. et al. Health-related quality of life in a cohort of adult patients with mild hemophilia A. J Thromb Haemost 2008; 06: 755-761. DOI:10.1111/j.1538-7836.2008.02929.x.
- 11 Hofstede FG. et al. Obesity: a new disaster for haemophilic patients? A nationwide survey. Haemophilia 2008; 14: 1035-1038. DOI:10.1111/j.1365-2516.2008.01806.x.
- 12 Fransen van de Putte DE. et al. Non-fatal cardiovascular disease, malignancies and other co-morbidity in adult haemophilia patients. Thromb Res 2012; 130: 157-162. DOI:10.1016/j.thromres.2011.12.012.
- 13 Primatesta P, Poulter NR. Improvement in hypertension management in England: results from the Health Survey for England 2003. J Hypertens 2006; 24: 1187-1192. DOI:10.1097/01.hjh.0000226210.95936.bc.
- 14 Collins GS, Altman DG. An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study. Br Med J 2010; 340: c2442. DOI:10.1136/bmj.c2442.
- 15 Hippisley-Cox J. et al. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. Br Med J 2007; 335: 136. DOI:10.1136/bmj.39261.471806.55.
- 16 Hippisley-Cox J. et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. Br Med J 2008; 336: 1475-1482. DOI:10.1136/bmj.39609.449676.25.
- 17 Conroy RM. et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003. DOI:10.1016/S0195-668X(03)00114-3.
- 18 Sharathkumar AA. et al. Prevalence and risk factors of cardiovascular disease (CVD) events among patients with haemophilia: experience of a single haemophilia treatment centre in the United States (US). Haemophilia 2011; 17: 597-604. DOI:10.1111/j.1365-2516.2010.02463.x.
- 19 Wisniewska-Ligier M. et al. Lipid metabolism in children with chronic hepatitis C, A preliminary report. Hepatogastroenterology 2006; 53: 887-891.
- 20 Dai CY. et al. Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. J Hepatol 2008; 49: 9-16. DOI:10.1016/j.jhep.2008.03.016.
- 21 Berger JS. et al. Screening for cardiovascular risk in asymptomatic patients. J Am Coll Cardiol 2010; 55: 1169-1177. DOI:10.1016/j.jacc.2009.09.066.
- 22 Dent TH. Predicting the risk of coronary heart disease I. The use of conventional risk markers. Atherosclerosis 2010; 213: 345-351. DOI:10.1016/j.atherosclerosis.2010.06.019.